# Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

Article · David R. Gandara, Sarah M. Paul, Marcin Kowanetz, Erica Schleifman, Wei Zou, Yan Li, Achim Rittmeyer, Louis Fehrenbacher, Geoff A. Otto, Christine M. Malboeuf, Daniel S. Lieber, Doron Lipson, Jacob Silterra, Lukas C. Amler, Todd Riehl, Craig A. Cummings, Priti S. Hegde, Alan B. Sandler, Marcus D. Ballinger, David A. Fabrizio, Tony S.K. Mok, David S. Shames

- Archive id: doi:10.1038/s41591-018-0134-3
- Published: 2018-07-30
- Venue: Nature Medicine
- DOI: https://doi.org/10.1038/s41591-018-0134-3
- PMID: 30082870
- Citations: 1,156
- Source URL: https://doi.org/10.1038/s41591-018-0134-3
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.